| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| TENOFOVIR ALAFENAMIDE (has an active metabolite)
| TENOFOVIR ALAFENAMIDE |
ANTIINFECTIVES | ORAL | Cmax 0.33 MICROMOLAR Tmax 1 HOUR PPB 80 PERCENT HT 0.51 HOUR SOLUBILITY 4.7 MILLIGRAM / MILLILITER | HIV REVERSE TRANSCRIPTASE | HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE INHIBITOR CHEMBL247 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE Q72547 REVERSE TRANSCRIPTASE/RNASEH HUMAN IMMUNODEFICIENCY VIRUS 1 ENZYME HYDROLASE | EMA | |||
